Pharmicell
Pharmicell Co., Ltd., a biopharmaceutical company, develops and sells stem cell drugs in South Korea and internationally. The company operates in Biopharmaceutical Business and Biochemical Business divisions. It offers Cellgram_AMI that is manufactured using autologous bone marrow-derived mesenchymal stem cell to improve the ejection fraction in patients with acute myocardial infarction reperfuse… Read more
Pharmicell (005690) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.080x
Based on the latest financial reports, Pharmicell (005690) has a cash flow conversion efficiency ratio of 0.080x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.78 Billion) by net assets (₩110.43 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pharmicell - Cash Flow Conversion Efficiency Trend (2010–2024)
This chart illustrates how Pharmicell's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pharmicell Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pharmicell ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Companhia de Saneamento do Paraná - SANEPAR
SA:SAPR3
|
0.414x |
|
Build-A-Bear Workshop Inc
NYSE:BBW
|
0.055x |
|
Shanghai Aladdin Biochemical Technology Co. Ltd. A
SHG:688179
|
N/A |
|
Zhejiang Zanyu Technology Co Ltd
SHE:002637
|
0.028x |
|
China Zhonghua Geotechnical Engineering Co Ltd
SHE:002542
|
0.007x |
|
HALOSOURCE REG S
F:48H
|
-0.016x |
|
Surgical Science Sweden AB (publ)
PINK:SUSRF
|
-0.001x |
|
ASP Isotopes Inc. Common Stock
NASDAQ:ASPI
|
-0.092x |
Annual Cash Flow Conversion Efficiency for Pharmicell (2010–2024)
The table below shows the annual cash flow conversion efficiency of Pharmicell from 2010 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩86.44 Billion | ₩3.50 Billion | 0.040x | -72.46% |
| 2023-12-31 | ₩80.40 Billion | ₩11.81 Billion | 0.147x | +42.35% |
| 2022-12-31 | ₩76.66 Billion | ₩7.91 Billion | 0.103x | +226.26% |
| 2021-12-31 | ₩63.87 Billion | ₩-5.22 Billion | -0.082x | -152.00% |
| 2020-12-31 | ₩57.11 Billion | ₩8.98 Billion | 0.157x | +10828.39% |
| 2019-12-31 | ₩51.52 Billion | ₩-75.50 Million | -0.001x | -102.04% |
| 2018-12-31 | ₩47.49 Billion | ₩3.40 Billion | 0.072x | +300.00% |
| 2017-12-31 | ₩55.99 Billion | ₩-2.01 Billion | -0.036x | -442.90% |
| 2016-12-31 | ₩94.60 Billion | ₩988.97 Million | 0.010x | +132.06% |
| 2013-12-31 | ₩82.42 Billion | ₩-2.69 Billion | -0.033x | +72.09% |
| 2012-12-31 | ₩101.58 Billion | ₩-11.87 Billion | -0.117x | +40.15% |
| 2011-12-31 | ₩82.82 Billion | ₩-16.17 Billion | -0.195x | +77.02% |
| 2010-12-31 | ₩9.90 Billion | ₩-8.41 Billion | -0.850x | -- |